Biotechnology Analyst Biegler, along with Dr. Rory Shallis, MD from Yale University School of Medicine, preview ASH abstracts (Relevant companies SNDX KURA VOR APTO SYRS) with a focus on key updates expected in the treatment of AML on an Analyst/Industry conference call to be held on November 9 at 10 am.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNDX:
- Syndax price target lowered to $32 from $34 at Barclays
- Syndax reports Q3 EPS (73c), consensus (78c)
- Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- Syndax’s axatilimab shows safety and efficacy in graft-versus-host disease
Questions or Comments about the article? Write to editor@tipranks.com